ATE142107T1 - Verwendung von angiotensin-ii-antagonisten zur herstellung eines arzneimittels zur behandlung von hyperuricemie - Google Patents

Verwendung von angiotensin-ii-antagonisten zur herstellung eines arzneimittels zur behandlung von hyperuricemie

Info

Publication number
ATE142107T1
ATE142107T1 AT91309176T AT91309176T ATE142107T1 AT E142107 T1 ATE142107 T1 AT E142107T1 AT 91309176 T AT91309176 T AT 91309176T AT 91309176 T AT91309176 T AT 91309176T AT E142107 T1 ATE142107 T1 AT E142107T1
Authority
AT
Austria
Prior art keywords
angiotensin
antagonists
preparing
medicinal product
treating hyperuricemia
Prior art date
Application number
AT91309176T
Other languages
English (en)
Inventor
Mitsuyosi Nakasima
Kazuo Kamei
Mitsutaka Kanamaru
Ikuo Ohta
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE142107T1 publication Critical patent/ATE142107T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
AT91309176T 1990-10-08 1991-10-07 Verwendung von angiotensin-ii-antagonisten zur herstellung eines arzneimittels zur behandlung von hyperuricemie ATE142107T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP27021490 1990-10-08

Publications (1)

Publication Number Publication Date
ATE142107T1 true ATE142107T1 (de) 1996-09-15

Family

ID=17483133

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91309176T ATE142107T1 (de) 1990-10-08 1991-10-07 Verwendung von angiotensin-ii-antagonisten zur herstellung eines arzneimittels zur behandlung von hyperuricemie

Country Status (8)

Country Link
US (1) US5260322A (de)
EP (1) EP0480659B1 (de)
JP (1) JPH0662410B2 (de)
AT (1) ATE142107T1 (de)
CA (1) CA2052884C (de)
DE (1) DE69121827T2 (de)
DK (1) DK0480659T3 (de)
ES (1) ES2091877T3 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
RU2109736C1 (ru) * 1992-12-17 1998-04-27 Санкио Компани Лимитед Производные бифенила и способ их получения
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
MY129541A (en) 1996-06-25 2007-04-30 Novartis Ag Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
US5919774A (en) * 1996-12-10 1999-07-06 Eli Lilly And Company Pyrroles as sPLA2 inhibitors
PL337888A1 (en) 1997-07-03 2000-09-11 Du Pont Pharm Co Imidazoprimidines and imidazopyridines for use in treating neurological disorders
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
GB9803226D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
US6124463A (en) * 1998-07-02 2000-09-26 Dupont Pharmaceuticals Benzimidazoles as corticotropin release factor antagonists
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902461D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902459D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
GB0000625D0 (en) 2000-01-13 2000-03-01 Zeneca Ltd Chemical compounds
WO2001094350A1 (en) 2000-06-07 2001-12-13 Almirall Prodesfarma S.A. 6-phenylpyrrolopyrimidinedione derivatives
EP1317258B1 (de) 2000-06-28 2009-02-11 Merck & Co., Inc. Verwendung von allopurinol zur behandlung von bluthochdruck
SE0100873D0 (sv) * 2001-03-13 2001-03-13 Astrazeneca Ab Method of treatment
AU2002319627A1 (en) * 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
WO2003030937A1 (en) * 2001-10-05 2003-04-17 Ono Pharmaceutical Co., Ltd. Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists
DK1471054T3 (da) 2002-01-11 2009-11-09 Daiichi Sankyo Co Ltd Aminoalkohol-derivat eller phosphonsyre-derivat og medicinsk sammensætning, der indeholder disse
ES2208063B1 (es) 2002-04-01 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de la 4-(pirrolopirimidin-6-il)bencenosulfonamida.
US7141600B2 (en) * 2003-04-15 2006-11-28 The Regents Of The University Of California Small molecule inhibition of a PDZ-domain interaction
NZ549162A (en) 2004-02-24 2009-12-24 Sankyo Co Amino-pyrrol alcohol compounds
JP4675586B2 (ja) * 2004-06-23 2011-04-27 壽製薬株式会社 高血圧症及び血清高尿酸血症の重複発症の治療のための薬剤
EP1781609A4 (de) * 2004-07-01 2009-07-29 Univ California Inhibierung einer pdz-domänen-wechselwirkung durch kleine moleküle
KR20090102883A (ko) * 2004-09-02 2009-09-30 테바 파마슈티컬 인더스트리즈 리미티드 올메살탄 메독소밀의 정제
US20070054948A1 (en) * 2004-09-02 2007-03-08 Lilach Hedvati Purification of olmesartan medoxomil
NL2000351C2 (nl) 2005-12-22 2007-09-11 Pfizer Prod Inc Estrogeen-modulatoren.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
ME01294B (me) 2007-11-27 2013-06-20 Ardea Biosciences Inc Nova jedinjenja i kompozicije i metode upotrebe
WO2009102893A2 (en) 2008-02-14 2009-08-20 Amira Pharmaceuticals, Inc. CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
NZ588374A (en) 2008-04-30 2012-11-30 Wellstat Therapeutics Corp Tetrazole compounds for reducing uric acid
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
GEP20146177B (en) 2010-01-27 2014-10-10 Boehringer Ingelheim Int Pyrazole compounds as crth2 antagonists
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8759386B2 (en) 2011-01-24 2014-06-24 Boehringer Ingelheim International Gmbh Pyrazole compounds as CRTH2 antagonists
JP5999387B2 (ja) 2011-03-25 2016-09-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｒｔｈ２拮抗薬としてのピラゾール化合物
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Also Published As

Publication number Publication date
JPH0525043A (ja) 1993-02-02
EP0480659A3 (en) 1992-06-17
DK0480659T3 (da) 1996-09-23
CA2052884A1 (en) 1992-04-09
JPH0662410B2 (ja) 1994-08-17
US5260322A (en) 1993-11-09
DE69121827D1 (de) 1996-10-10
EP0480659B1 (de) 1996-09-04
CA2052884C (en) 2003-12-30
EP0480659A2 (de) 1992-04-15
ES2091877T3 (es) 1996-11-16
DE69121827T2 (de) 1997-02-27

Similar Documents

Publication Publication Date Title
ATE142107T1 (de) Verwendung von angiotensin-ii-antagonisten zur herstellung eines arzneimittels zur behandlung von hyperuricemie
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
ATE342728T1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
DE69307509D1 (de) Vorrichtung zur behandlung von herzfehlern
DE69031290D1 (de) Verwendung von Sertindol zur Behandlung von Schizophrenie
DE69124293D1 (de) Vorrichtung zur Behandlung von Wirbelsäulenerkrankungen
ATE256463T1 (de) Pharmazeutische zubereitung zur verwendung in der behandlung von diabetes
DE69507029D1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
DE3780972D1 (de) Verwendung von spezifischen n-methyl-d-aspartat-rezeptor-antagonisten zur praevention und behandlung von neurodegeneration.
ATE411026T1 (de) Mittel zur behandlung der alzheimer-krankheit
DE68912459D1 (de) Verwendung von Thromboxan-A2-Rezeptorantagonisten zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Hautkrankheiten.
NO902800D0 (no) Fremgangsmaate for fremstilling av 11beta-aryl-4-oestrener.
DE3788057D1 (de) Verwendung von heterocyclischen Verbindungen zur Behandlung von Depressionen.
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE201828T1 (de) Verwendung eines cgrp antagonisten zur behandlung von flechten und pruritus und so erhaltene zubereitung
DE69431199D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
DE59109130D1 (de) Arzneimittel enthaltend einen quisqualat-rezeptor-antagonisten und einen dopamin-agonisten zur behandlung des morbus parkinson
FI101849B1 (fi) Antimikrobiset koostumukset ja niiden käyttö silmälääkkeiden säilömiseksi ja piilolinssien hoitamiseksi
DE3686097D1 (de) Verwendung von dopamin-agonisten zur herstellung eines arzneimittels zur behandlung von psychostimulant-sucht.
ATA67688A (de) Neue 3-(2-haloalkyl)-1,4-oxathiine und 2-(2-halo- alkyl)-1,4-dithiine sowie pharmazeutische zusammensetzungen mit diesen verbindungen zur behandlung von leukaemie und tumoren
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
ATE230608T1 (de) Verwendung von bradykinin-antagonisten zur herstellung von arzneimitteln zur behandlung und prävention der alzheimer'schen krankheit
DE59410340D1 (de) Verwendung von Bradykinin-Antagonisten zur Behandlung von Viruserkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time